IHL - INCANNEX - HOLDERS RESEARCH, page-1079

Mate,

I have not been a student of the macros mate.
I am sure there are more well-educated posters, schooled in Finance / Economics (@Lupe @rhino78 @Flectional ) and the like that could most likely better answer your questions.

Some commentary here has been ludicrous, to say the least. (Joel's management style or the lack of communication/s)

I don't believe that IHL is immune from the macro environment as some would argue and try to make us believe.
To ignore the influences of institutional withdrawals from one sector in favor of another doesn't make sense to me either.
It is very interesting reading from an educational standpoint.

"Longer-term yields exert a profound influence on the costs of various financial products, including mortgages, auto loans, and stocks. Sustaining current yield levels or even further increases without triggering an economic slowdown seems challenging to us. High yields are a strong brake on economic growth. Besides their direct impact on consumer finances, high yields also send deficits soaring, for federal debt now has to be serviced by borrowing at ever higher interest rates.This is an unfolding situation, but we believe it will be a challenge for the economy to continue growing consistently with such a high yield burden. Any sign of a slowdown will push longer-term yields lower, which should be generally favorable for biotechs.

Inflation progress might be uneven, yet it is unmistakably on a downward trajectory. China's role as a global growth engine and its struggles this year with deflationary forces and diminishing demand are contributing to global progress on inflation. With China's consumer prices falling for the first time in over two years and producer prices declining year-over-year for the past 10 months, the ongoing demand recession aids in controlling inflation. Consequently, a China slowdown reduces demand pressures and fosters supply chain healing at a time when the resiliency of U.S. economic growth contributes towards pricing pressures."https://prudentbiotech.com/second-half-outlook-for-biotech-stocks/

More research is required to get better answers to your questions mate.

Good luck @skrillmux